血浆循环无细胞 DNA 和配对白细胞联合突变测序在治疗反应预测中的潜力。
The potential of combined mutation sequencing of plasma circulating cell-free DNA and matched white blood cells for treatment response prediction.
机构信息
Laboratory of Molecular Pathology, Department of Pathology (EA10), University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.
出版信息
Mol Oncol. 2020 Mar;14(3):487-489. doi: 10.1002/1878-0261.12646. Epub 2020 Feb 23.
Abstract
Highly sensitive mutation detection methods enable the application of circulating cell-free DNA for molecular tumor profiling. Recent studies revealed that sequencing artifacts, germline variants, and clonal hematopoiesis confound the interpretation of sequencing results and complicate subsequent treatment decision making and disease monitoring. Parallel sequencing of matched white blood cells promises to overcome these issues and enables appropriate variant calling. Comment on: https://doi.org/10.1002/1878-0261.12617.
摘要
高灵敏度突变检测方法使循环无细胞 DNA 在分子肿瘤分析中的应用成为可能。最近的研究表明，测序伪影、种系变异和克隆性造血会干扰测序结果的解释，使后续的治疗决策和疾病监测变得复杂。配对白细胞的平行测序有望克服这些问题，并实现适当的变异调用。评论：https://doi.org/10.1002/1878-0261.12617。
相似文献
1
The potential of combined mutation sequencing of plasma circulating cell-free DNA and matched white blood cells for treatment response prediction.血浆循环无细胞 DNA 和配对白细胞联合突变测序在治疗反应预测中的潜力。
Mol Oncol. 2020 Mar;14(3):487-489. doi: 10.1002/1878-0261.12646. Epub 2020 Feb 23.
2
Metastatic Colorectal Cancer Treatment Response Evaluation by Ultra-Deep Sequencing of Cell-Free DNA and Matched White Blood Cells.基于游离细胞 DNA 和配对白细胞的超高深度测序评估转移性结直肠癌的治疗反应。
Clin Cancer Res. 2023 Mar 1;29(5):899-909. doi: 10.1158/1078-0432.CCR-22-2538.
3
High-intensity sequencing reveals the sources of plasma circulating cell-free DNA variants.高通量测序揭示了血浆游离循环 DNA 变异体的来源。
Nat Med. 2019 Dec;25(12):1928-1937. doi: 10.1038/s41591-019-0652-7. Epub 2019 Nov 25.
4
Plasma cell-free DNA variant analysis compared with methylated DNA analysis in renal cell carcinoma.血浆无细胞游离 DNA 变异分析与肾细胞癌中甲基化 DNA 分析的比较。
Genet Med. 2020 Aug;22(8):1366-1373. doi: 10.1038/s41436-020-0801-x. Epub 2020 Apr 28.
5
Protocol optimization of a targeted sequencing panel for genomic profiling of bronchoalveolar lavage fluid in lung cancer.针对肺癌支气管肺泡灌洗液进行基因组分析的靶向测序panel 的方案优化。
Cancer Med. 2023 Sep;12(17):17632-17637. doi: 10.1002/cam4.6380. Epub 2023 Aug 17.
6
Matched Molecular Profiling of Cell-Free DNA and Tumor Tissue in Patients With Advanced Clear Cell Renal Cell Carcinoma.晚期透明细胞肾细胞癌患者的游离 DNA 和肿瘤组织的配对分子分析。
JCO Precis Oncol. 2022 Jul;6:e2200012. doi: 10.1200/PO.22.00012.
7
Personalized Cancer Monitoring Assay for the Detection of ctDNA in Patients with Solid Tumors.用于检测实体瘤患者 ctDNA 的个体化癌症监测检测。
Mol Diagn Ther. 2023 Nov;27(6):753-768. doi: 10.1007/s40291-023-00670-1. Epub 2023 Aug 26.
8
Noninvasive detection of tumor-associated mutations from circulating cell-free DNA in hepatocellular carcinoma patients by targeted deep sequencing.通过靶向深度测序对肝细胞癌患者循环游离DNA中的肿瘤相关突变进行无创检测。
Oncotarget. 2016 Jun 28;7(26):40481-40490. doi: 10.18632/oncotarget.9629.
9
The Landscape of Actionable Genomic Alterations in Cell-Free Circulating Tumor DNA from 21,807 Advanced Cancer Patients.21807 例晚期癌症患者的游离循环肿瘤 DNA 中可操作基因组改变的全景分析。
Clin Cancer Res. 2018 Aug 1;24(15):3528-3538. doi: 10.1158/1078-0432.CCR-17-3837. Epub 2018 May 18.
10
Multi-region sequencing reveals genetic correlation between esophageal squamous cell carcinoma and matched cell-free DNA.多区域测序揭示食管鳞癌与匹配的游离 cfDNA 之间的遗传相关性。
Cancer Genet. 2021 Nov;258-259:93-100. doi: 10.1016/j.cancergen.2021.08.005. Epub 2021 Aug 30.
引用本文的文献
1
Sequencing paired tumor DNA and white blood cells improves circulating tumor DNA tracking and detects pathogenic germline variants in localized colon cancer.对配对的肿瘤 DNA 和白细胞进行测序可改善循环肿瘤 DNA 的跟踪，并在局部结肠癌中检测到致病性种系变异。
ESMO Open. 2023 Dec;8(6):102051. doi: 10.1016/j.esmoop.2023.102051. Epub 2023 Nov 10.
2
Liquid Profiling for Cancer Patient Stratification in Precision Medicine-Current Status and Challenges for Successful Implementation in Standard Care.精准医学中用于癌症患者分层的液体分析——当前现状及在标准护理中成功实施面临的挑战
Diagnostics (Basel). 2022 Mar 19;12(3):748. doi: 10.3390/diagnostics12030748.
3
Circulating tumor DNA as a biomarker for monitoring early treatment responses of patients with advanced lung adenocarcinoma receiving immune checkpoint inhibitors.循环肿瘤 DNA 作为生物标志物，用于监测接受免疫检查点抑制剂治疗的晚期肺腺癌患者的早期治疗反应。
Mol Oncol. 2021 Nov;15(11):2910-2922. doi: 10.1002/1878-0261.13090. Epub 2021 Sep 25.
4
Validation of a Circulating Tumor DNA-Based Next-Generation Sequencing Assay in a Cohort of Patients with Solid tumors: A Proposed Solution for Decentralized Plasma Testing.基于循环肿瘤 DNA 的下一代测序检测在实体瘤患者队列中的验证：去中心化血浆检测的一种解决方案。
Oncologist. 2021 Nov;26(11):e1971-e1981. doi: 10.1002/onco.13905. Epub 2021 Aug 4.
5
Mass Spectrometry as a Highly Sensitive Method for Specific Circulating Tumor DNA Analysis in NSCLC: A Comparison Study.质谱分析法作为非小细胞肺癌中特定循环肿瘤DNA分析的高灵敏度方法：一项比较研究
Cancers (Basel). 2020 Oct 16;12(10):3002. doi: 10.3390/cancers12103002.
6
Machine Learning-Assisted Evaluation of Circulating DNA Quantitative Analysis for Cancer Screening.机器学习辅助的循环DNA定量分析在癌症筛查中的评估
Adv Sci (Weinh). 2020 Jul 29;7(18):2000486. doi: 10.1002/advs.202000486. eCollection 2020 Sep.
7
Clinical significance of clonal hematopoiesis in the interpretation of blood liquid biopsy.克隆性造血在液体活检解读中的临床意义。
Mol Oncol. 2020 Aug;14(8):1719-1730. doi: 10.1002/1878-0261.12727. Epub 2020 Jun 8.
8
Comparison of Circulating Cell-Free DNA Extraction Methods for Downstream Analysis in Cancer Patients.癌症患者下游分析中循环游离DNA提取方法的比较
Cancers (Basel). 2020 May 13;12(5):1222. doi: 10.3390/cancers12051222.
本文引用的文献
1
Orthogonal Comparison of Four Plasma NGS Tests With Tumor Suggests Technical Factors are a Major Source of Assay Discordance.四项血浆NGS检测与肿瘤的正交比较表明技术因素是检测不一致的主要来源。
JCO Precis Oncol. 2019 Dec;3:1-9. doi: 10.1200/PO.18.00191.
2
High ctDNA molecule numbers relate with poor outcome in advanced ER+, HER2- postmenopausal breast cancer patients treated with everolimus and exemestane.ctDNA 分子数量高与接受依维莫司和依西美坦治疗的晚期 ER+/HER2-绝经后乳腺癌患者预后不良相关。
Mol Oncol. 2020 Mar;14(3):490-503. doi: 10.1002/1878-0261.12617. Epub 2020 Feb 7.
3
Mutant p53 drives clonal hematopoiesis through modulating epigenetic pathway.突变型 p53 通过调节表观遗传通路驱动克隆性造血。
Nat Commun. 2019 Dec 11;10(1):5649. doi: 10.1038/s41467-019-13542-2.
4
Assessing clonal haematopoiesis: clinical burdens and benefits of diagnosing myelodysplastic syndrome precursor states.评估克隆性造血：诊断骨髓增生异常综合征前驱状态的临床负担与益处
Lancet Haematol. 2020 Jan;7(1):e73-e81. doi: 10.1016/S2352-3026(19)30211-X. Epub 2019 Dec 3.
5
High-intensity sequencing reveals the sources of plasma circulating cell-free DNA variants.高通量测序揭示了血浆游离循环 DNA 变异体的来源。
Nat Med. 2019 Dec;25(12):1928-1937. doi: 10.1038/s41591-019-0652-7. Epub 2019 Nov 25.
6
Multicenter Evaluation of Circulating Cell-Free DNA Extraction and Downstream Analyses for the Development of Standardized (Pre)analytical Work Flows.多中心评估循环游离 DNA 提取及其下游分析，以制定标准化（术前）分析流程。
Clin Chem. 2020 Jan 1;66(1):149-160. doi: 10.1373/clinchem.2019.306837.
7
Untargeted Assessment of Tumor Fractions in Plasma for Monitoring and Prognostication from Metastatic Breast Cancer Patients Undergoing Systemic Treatment.对接受全身治疗的转移性乳腺癌患者血浆中的肿瘤分数进行非靶向评估以进行监测和预后判断
Cancers (Basel). 2019 Aug 14;11(8):1171. doi: 10.3390/cancers11081171.
8
Targeted deep sequencing revealed variants in cell-free DNA of hormone receptor-positive metastatic breast cancer patients.靶向深度测序揭示了激素受体阳性转移性乳腺癌患者游离 DNA 中的变异。
Cell Mol Life Sci. 2020 Feb;77(3):497-509. doi: 10.1007/s00018-019-03189-z. Epub 2019 Jun 28.
9
Liquid biopsy and minimal residual disease - latest advances and implications for cure.液体活检与微小残留病灶——最新进展及其对治愈的影响。
Nat Rev Clin Oncol. 2019 Jul;16(7):409-424. doi: 10.1038/s41571-019-0187-3.
10
Current and future perspectives of liquid biopsies in genomics-driven oncology.液体活检在基于基因组学的肿瘤学中的现状与未来展望。
Nat Rev Genet. 2019 Feb;20(2):71-88. doi: 10.1038/s41576-018-0071-5.
Zotero 插件